Saxagliptin

본문 바로가기


Home > Product > Saxagliptin
Selling leads
Saxagliptin
Posting date : Jun 30, 2025
Membership
Free Member Scince Jun 27, 2025
FOB Price
detailed discussion
Min. Order Quantity
1
Supply Abillity
hundreds of kgs
Port
Shanghai Port
Payment Terms
detailed discussion
Package
Convenient package
Keyword :
Category
Contact
Lena
Selling Leads Detail
Company Info
 
Quick Detail
Place of Origin
China [CN]
Brand Name
Royal
Model Number
+86 15242851296
HS-CODE
-
Package & Delivery Lead Time
Package
Convenient package
Detailed Description

Saxagliptin is a type 2 diabetes treatment drug that can stimulate the pancreas to produce more insulin after meals. It was jointly developed by Astrazeneca of the United States and Bristol-Myers Squibb and belongs to dipeptidyl peptidase-4 (DPP-IV) inhibitors. On July 31, 2009, Astrazeneca and Bristol-Myers Squibb jointly developed a new type 2 diabetes drug - Onglyza tablets based on Chemicalbook, which was approved by the US FDA for marketing. It is used to treat adult type 2 diabetes once daily, while controlling diet and increasing exercise. The most common side effects are upper respiratory tract infections, urinary tract infections and headaches. Other side effects include allergic reactions such as rashes and urticaria.


ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us
Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea
About Us Privacy Policy Terms of use Copyright © 2000-2026 ECROBOT.COM. All rights reserved.
Top